Observation on the Efficacy of Roxadustat in Treating Low-risk Myelodysplastic Syndrome
Abstract
Objective: To observe the effect of different doses and frequencies of roxadustat on low-risk patients with myelodysplastic syndromes (MDS). Methods: This study was conducted using a comparative treatment observation approach. Low-risk MDS patients admitted to our hospital from February 2022 to February 2023 were selected, excluding patients with a history of severe drug allergies or known allergies to roxadustat. A total of 60 patients were included and randomly divided into observation group A (20 cases, 100 mg, twice weekly), observation group B (20 cases, 50 mg, once daily), and observation group C (20 cases, 150 mg, twice weekly). Patient recovery, adverse reaction rate, and hemoglobin recovery time were compared and statistically analyzed. Results: The recovery rate of group B in the observation group was significantly higher than that in the other two groups, and the incidence of adverse reactions and the time to Hb recovery were also better in group B than in the other two groups (p < 0.05). Conclusion: Low-dose, high-frequency (50 mg, once daily) administration can effectively improve the hemoglobin level of low-risk MDS patients and help improve their general survival.
References
Chiereghin C, Travaglino E, Zampini M, et al., 2021, The Genetics of Myelodysplastic Syndromes: Clinical Relevance. Genes, 12(8): 1144.
Zhao H, 2022, Analysis of Gene Mutation Characteristics of Myelodysplastic Syndrome and Molecular Epidemiological Study on Its Prognosis, thesis, Shandong University.
Dan C, Chi J, Wang L, 2015, Molecular Mechanisms of the Progression of Myelodysplastic Syndrome to Secondary Acute Myeloid Leukaemia and Implication for Therapy. Ann Med, 47(3): 209–217.
Li L, Ma T, Zhang L, 2022, Treatment Options for Low-Risk Myelodysplastic Syndrome. Chinese Journal of Practical Internal Medicine, 42(07): 546–551.
Chinese Society of Hematology, Chinese Medical Association, 2019, Chinese Guidelines for the Diagnosis and Management of Myelodysplastic Syndromes (2019 Edition). Chinese Journal of Hematology, 40(2): 89–94.
Glenthøj A, Ørskov AD, Hansen JW, et al., 2016, Immune Mechanisms in Myelodysplastic Syndrome. International Journal of Molecular Sciences, 17(6): 944.
Zhang W, 2021, Clinical Characteristics, Cytogenetic Features and Prognostic Value of 60 Patients with Myelodysplastic Syndrome, thesis, Anhui Medical University.
Dhillon S, 2019, Roxadustat: First Global Approval. Drugs, 79(5): 563–572.
Chen N, Hao C, Peng X, et al., 2019, Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. The New England Journal of Medicine, 381(11): 1001–1010.
Henry H, Glaspy J, Harrup R, et al., 2022, Roxadustat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome: Open-Label, Dose-Selection, Lead-In Stage of a Phase 3 Study. American Journal of Hematology, 97(2): 174–184.
Chen Y, Zhang L, Wang L, et al., 2023, Analysis of Influencing Factors on the Clinical Efficacy of Roxadustat in the Treatment of Renal Anemia. Journal of Inner Mongolia Medical University, 45(2): 185–188 + 192.
Jin J, Zhang L, Wang Y, et al., 2020, Application Effect of Enhanced Recovery After Surgery Nursing in Patients Undergoing Cervical Single-Door Laminoplasty. Chinese Journal of Modern Nursing, 26(7): 917–923.
Cheson D, Greenberg L, Bennett M, et al., 2006, Clinical Application and Proposal for Modification of the International Working Group (IWG) Response Criteria in Myelodysplasia. Blood, 108(2): 419–425.
Zhang Q, 2019, Analysis of Influencing Factors of Chemotherapy Toxicity in Elderly Patients with Colon Cancer and Discussion on the Predictive Value of CARG Tool, thesis, Soochow University.
Liu X, Wang LN, Liu CX, et al., 2020, Effects of HAG Combined with Decitabine on the Expression of Inflammatory Factors, HIF-1α and VEGF in Patients with Myelodysplastic Syndrome. Hebei Medical Journal, 42(20): 3123–3126.
Chen N, Hao C, Liu BC, et al., 2019, Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. The New England Journal of Medicine, 381(11): 1011–1022.
Ma J, 2020, Research Progress on the Role of DEAD-Box RNA Helicase 41 in Myeloid Tumors—Myelodysplastic Syndrome and Acute Myeloid Lymphocytic Leukemia. Journal of Taizhou University, 42(06): 46–51 + 62.
Wang Q, Chen Y, Chen J, et al., 2021, Screening of Long Non-Coding RNA SET2-1 Related to ABAT Gene in Myelodysplastic Syndrome by Integrated Regulatory Network Analysis and Its Effect on Cell Proliferation and Apoptosis. Fudan University Journal of Medical Sciences, 48(1): 17–25.
Ikenoue T, Furumatsu Y, Kitamura T, 2021, Transfusion-Dependent Anaemia Treatment Using Continuous Erythropoietin Receptor Activator (Epoetin β Pegol) and Roxadustat After Darbepoetin Treatment Failure in Low-Risk Myelodysplastic Syndrome: A Case Report. Oxford Medical Case Reports, 2021(5): omab026.
